Integer Holdings Co. (NYSE:ITGR) Given Consensus Rating of “Moderate Buy” by Brokerages

Integer Holdings Co. (NYSE:ITGR) has earned an average rating of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $142.00.

A number of research firms recently commented on ITGR. Piper Sandler reaffirmed an “overweight” rating and set a $140.00 target price (up previously from $125.00) on shares of Integer in a report on Friday, October 25th. KeyCorp upped their price objective on shares of Integer from $139.00 to $144.00 and gave the company an “overweight” rating in a report on Tuesday, October 15th. Truist Financial reduced their target price on shares of Integer from $150.00 to $147.00 and set a “buy” rating for the company in a report on Friday, October 25th. Citigroup upped their price target on shares of Integer from $124.00 to $130.00 and gave the company a “neutral” rating in a report on Tuesday, October 1st. Finally, Benchmark lifted their price objective on Integer from $130.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, October 21st.

Hedge Funds Weigh In On Integer

A number of large investors have recently bought and sold shares of ITGR. TD Private Client Wealth LLC increased its holdings in Integer by 15.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,420 shares of the medical equipment provider’s stock worth $185,000 after acquiring an additional 191 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Integer by 1.2% during the third quarter. Geode Capital Management LLC now owns 764,528 shares of the medical equipment provider’s stock worth $99,408,000 after purchasing an additional 9,421 shares in the last quarter. Public Employees Retirement System of Ohio raised its position in shares of Integer by 3,443.4% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 13,890 shares of the medical equipment provider’s stock worth $1,806,000 after purchasing an additional 13,498 shares during the last quarter. XTX Topco Ltd lifted its stake in Integer by 31.5% in the 3rd quarter. XTX Topco Ltd now owns 6,764 shares of the medical equipment provider’s stock valued at $879,000 after buying an additional 1,620 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in Integer by 23.3% in the 3rd quarter. Jane Street Group LLC now owns 151,397 shares of the medical equipment provider’s stock worth $19,682,000 after buying an additional 28,572 shares during the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Stock Up 0.1 %

NYSE:ITGR opened at $139.39 on Monday. The company’s 50 day moving average is $132.63 and its two-hundred day moving average is $125.17. The company has a market cap of $4.68 billion, a PE ratio of 43.02, a P/E/G ratio of 2.02 and a beta of 1.12. Integer has a twelve month low of $86.42 and a twelve month high of $142.76. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67.

Integer (NYSE:ITGR) last released its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.07. Integer had a return on equity of 11.63% and a net margin of 6.70%. The firm had revenue of $431.42 million for the quarter, compared to the consensus estimate of $440.59 million. During the same period in the prior year, the firm earned $1.27 EPS. The firm’s revenue was up 8.7% on a year-over-year basis. Analysts anticipate that Integer will post 5.33 EPS for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.